Dose reductions to either [177Lu]Lu-PSMA-I&T (20% reduction) or 223Ra (20–25% reduction) will be considered for treatment-related AEs of grade 3 or higher, with the exception of grade 2 xerostomia and dry eyes also warranting a dose reduction to [177Lu]Lu-PSMA-I&T. This evidence concerns the gene FOLH1 and dry eye syndrome.